




2025 GNIPST BULLETIN

(Pharmacy)

Volume-2, Issue- 3




**GURU NANAK INSTITUTE OF PHARMACEUTICAL
SCIENCE AND TECHNOLOGY**

157/F, Nilgunj Road, Kolkata- 700114, West Bengal, India



Table of Contents

1	Message from Director and Principal	1
2	Recent Researches	2
3	New Drug Approvals	3
4	Clinical Trial News	4
5	Disease Outbreak News	5
6	Campus News	6
7	Special Pages	7
8	Game Time	8





MESSAGE FROM HONORABLE DIRECTOR

As the Director of Guru Nanak Institute of Pharmaceutical Science and Technology, I extend my heartfelt greetings to all the incredible women who inspire, lead, and contribute to our institution and beyond. On this special occasion of International Women's Day, we celebrate your strength, resilience, and invaluable contributions to society. At our esteemed institution, we remain steadfast in fostering an environment

that empowers women through education, innovation, and holistic development. We take pride in nurturing inquisitive minds, inspiring critical thinking, and equipping our students—especially our young women—with the skills and confidence to excel in the field of Pharmaceutical Sciences.

As we move forward in 2025, we reaffirm our commitment to creating an inclusive and progressive academic community, where talent thrives, and aspirations turn into achievements. Your dedication, perseverance, and unwavering spirit continue to shape the future, and we are deeply grateful for your contributions.

Wishing you all a **Happy Women's Day** filled with joy, success, and fulfillment!

Prof. (Dr.) Abhijit Sengupta

MESSAGE FROM HONORABLE PRINCIPAL

On this special occasion of International Women's Day, I extend my heartfelt wishes to all our students, faculty, staff, and partners. May this year bring you good health, happiness, and success.

At Guru Nanak Institute of Pharmaceutical Science and Technology (GNIPST), we take immense pride in fostering a

learning environment that empowers women to excel in academics, research, and leadership. Since our inception in 2005, GNIPST has remained dedicated to delivering high-quality pharmacy education, earning recognition from the Pharmacy Council of India (PCI) and establishing itself as a leader in pharmacy education in West Bengal. We are proud to be the first pharmacy institute in the region to receive accreditation from both NAAC and NBA, and our recognition as an NIRF-ranked pharmacy institute (74th position in 2024) reflects our unwavering commitment to academic and professional excellence.


This Women's Day, we celebrate the achievements, dedication, and resilience of women in academia, healthcare, and research. At GNIPST, we continue to encourage and support women in science and technology, ensuring they have the opportunities and resources to innovate, lead, and make meaningful contributions to society.

As we approach 2025, our focus remains on fostering a progressive and inclusive academic community, where all students, especially young women, are encouraged to pursue their ambitions with confidence. We welcome aspiring pharmacy professionals to join us in this journey of knowledge, discovery, and growth.

Here's to a future of empowerment, excellence, and boundless opportunities for all!

Prof. (Dr.) Lopamudra Datta





RECENT RESEARCHES



WHO announces new collaborating centre on AI for health governance

MORE INFO

www.who.int/

The World Health Organization (WHO) today designated the Digital Ethics Centre at Delft University of Technology in the Netherlands as a WHO Collaborating Centre on artificial intelligence (AI) for health governance. AI has the potential to re-shape health care, save lives and improve health and well-being. However, harnessing its benefits for good requires collaboration from stakeholders committed to robust governance, ethical safeguards, and evidence-based policies. The WHO Collaborating Centre designation recognizes the Digital Ethics Centre at Delft University of Technology's decades-long history of cutting-edge research on responsible innovation, and its leadership in incorporating ethical values into design requirements for digital technologies. This inauguration marks the continuation of a strong partnership between the Digital Ethics Centre and WHO with the two entities jointly organizing international consultations, workshops, and the development of normative guidance and training in the past.

Falsified (contaminated) OXYCONTIN 80mg identified in the WHO European Region

MORE INFO

www.who.int/

This WHO Medical Product Alert refers to one batch of falsified OXYCONTIN 80mg (oxycodone hydrochloride). The falsified product was detected in the unregulated market in Switzerland and reported to WHO in February 2025 by the genuine manufacturer MUNDIPHARMA. The falsified product imitates genuine OXYCONTIN 80mg authorized in Poland. OXYCONTIN (oxycodone hydrochloride) is a semi-synthetic opioid indicated for the treatment of moderate to severe pain. Laboratory testing of samples of the falsified product was conducted by the Drug Information Centre of the City of Zurich (DIZ), Switzerland. DIZ's drug checking service determined that the tablets did not contain oxycodone, but a synthetic opioid likely to be a nitazene compound. Nitazene derivatives (e.g., metonitazene, isotonitazene, fluonitazene) are potent synthetic opioids, primarily used in research due to their high addiction potential and severe side-effects. These substances can be hundreds of times stronger than oxycodone, posing a high overdose risk. Limited information is available on their risks, toxicity, side-effects, and long-term consequences.



FDA

NEW DRUG APPROVALS

January, 2025

**Gomekli (mirdametinib)
Capsules and Tablets for
Oral Suspension**

- Date of Approval: February 11, 2025
- Company: SpringWorks Therapeutics, Inc.
- Treatment for: Neurofibromatosis



**Romvimza (vimseltinib)
Capsules**

- Date of Approval: February 14, 2025
- Company: Deciphera Pharmaceuticals, Inc.
- Treatment for: Tenosynovial Giant Cell Tumor



Ospomyv (denosumab-dssb) Injection

- Date of Approval: February 13, 2025
- Company: Samsung Bioepis Co., Ltd.
- Treatment for: Osteoporosis



Ctexli (chenodiol) Tablets

- Date of Approval: February 21, 2025
- Company: Mirum Pharmaceuticals Inc.
- Treatment for: Cerebrotendinous Xanthomatosis



Miudella (copper) Intrauterine System

- Date of Approval: February 24, 2025
- Company: Sebela Women's Health Inc.
- Treatment for: Birth Control



Stoboclo (denosumab-bmwo) Injection – formerly CT-P41

- Date of Approval: February 28, 2025
- Company: Celltrion
- Treatment for: Osteoporosis



Osenvelt (denosumab-bmwo) Injection – formerly CT-P41

- Date of Approval: February 28, 2025
- Company: Celltrion
- Treatment for: Osteolytic Bone Lesions of Multiple Myeloma.



<https://www.drugs.com/newdrugs.html>





CLINICAL TRIAL NEWS



01.

BlueRock Therapeutics Receives FDA Fast Track Designation for OpCT-001 for the Treatment of Primary Photoreceptor Diseases

Berlin, Germany, and Cambridge, MA, USA February 27, 2025 – Bayer AG and BlueRock Therapeutics LP, a clinical-stage cell therapy company and wholly owned subsidiary of Bayer AG, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for OpCT-001, an investigational induced pluripotent stem cell (iPSC)-derived cell therapy for the treatment of primary photoreceptor diseases.

02.

Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer

BOSTON, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to PYX-201 for the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) whose disease has progressed following treatment with platinum-based chemotherapy and an anti-PD-(L)1 antibody.

03.

Emalex Biosciences' Lead Candidate Meets Primary and Secondary Endpoints in Phase 3 Tourette Syndrome Study

CHICAGO – February 25, 2025 – Emalex Biosciences announced positive topline data from its Phase 3 registrational study of ecopipam, a novel dopamine-1 receptor antagonist, in subjects with Tourette syndrome.

04.

U.S. FDA Accepts Gilead's New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review

FOSTER CITY, Calif.--(BUSINESS WIRE) February 18, 2025 -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions for lenacapavir – the company's twice-yearly injectable HIV-1 capsid inhibitor – for the prevention of HIV as pre-exposure prophylaxis (PrEP).

05.

FDA Grants Fast Track Designation to PleoPharma, Inc's Investigational New Drug, PP-01, for the Mitigation of Cannabis Withdrawal Symptoms in Patients With Cannabis Use Disorder

PHOENIXVILLE, Pa., Feb. 13, 2025 /PRNewswire/ -- PleoPharma, Inc., a privately held company focused on finding treatments for cannabis related health issues, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PP-01, its lead asset, for the mitigation of Cannabis Withdrawal Syndrome in patients with Cannabis Use Disorder.


06.

Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers

HOUSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) announces that patient enrollment will resume in the investigator-initiated Phase 1/2 clinical trial evaluating seclidemstat in combination with azacitidine for the treatment of myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). The trial is being conducted at the University of Texas MD Anderson Cancer Center (MDACC) and is listed as recruiting on clinical trials.gov – trial NCT04734990.

MORE INFORMATION >>

https://www.drugs.com/clinical_trials_archive/january-2025.html





DISEASE OUTBREAK NEWS (DONS)

February, 2025

Marburg Virus Disease–United Republic of Tanzania

14 February 2025

Situation at a glance

Since the declaration of the Marburg Virus Disease (MVD) outbreak on 20 January 2025 in the United Republic of Tanzania, one additional confirmed death was reported by the Ministry of Health from the epicentre of the outbreak in Biharamulo district in Kagera region. As of 10 February 2025, a cumulative of two confirmed and eight probable cases were reported by the Ministry of Health. All 10 cases have died, including eight who died before the confirmation of the outbreak. As of 10 February 2025, all 281 contacts that were listed and under monitoring have completed the 21-day follow-up. The Ministry of Health developed a national response plan to guide activities. Additionally, a national rapid response team was deployed to the affected region to enhance outbreak investigation and response, with technical and operational support from WHO and health partners.



MORE INFO

<https://www.who.int/emergencies/disease-outbreak-news/item/2024-DON547>

Sudan virus disease - Uganda

21 February 2025

Situation at a glance

As of 20 February 2025, a total of nine confirmed cases of Sudan virus disease, including one death have been reported from Uganda, since the outbreak was declared on 30 January 2025. Eight cases received care at treatment centres in the capital Kampala and in Mbale and were discharged on 18 February after two negative tests 72 hours apart. As of 20 February 2025, 58 contacts that have been identified are still under follow up in designated quarantine facilities located in Jinja, Kampala, and Mbale. Sudan virus disease belongs to the same family as Ebola virus disease. It is caused by Sudan virus (SUDV). It is a severe disease with high case fatality ranging from 41% to 70% in past outbreaks. In the absence of licensed vaccines and therapeutics for the prevention and treatment of SVD, the risk of potential serious public health impact is high. Early detection, diagnosis, and optimized supportive care may increase the chance of survival.



MORE INFO


<https://www.who.int/emergencies/disease-outbreak-news/item/2024-DON548>



GNIPST BULLETIN 2025

yes girl, you can.

CAMPUS NEWS



1. Youngotsav 2025: The vibrant spirit of youth took over GNIPST college campus as Youngotsav 2025 arrived in full swing on 3rd March 2025 from 12 PM onwards, bringing with it an explosion of energy, talent, and celebration. The much-anticipated ultimate youth carnival lived up to its hype, offering students a thrilling day filled with non-stop entertainment and camaraderie.



3. IRIS 2K25: From March 6th to 8th, 2025, the Guru Nanak Institute of Pharmaceutical Science and Technology (GNIPST) hosted its annual cultural fest, IRIS 2K25, on the GNCC campus. This vibrant event brought together students from various schools and colleges, offering a platform to showcase their talents across diverse programs.



2. Jan Aushadhi Diwas : On March 5, 2025, the Guru Nanak Institute of Pharmaceutical Science and Technology (GNIPST) celebrated **Jan Aushadhi Diwas** by organizing a National Seminar titled "**The Janaushadhi Sangoshtthi: Quality Medicine Made Affordable and Accessible.**" This event was part of the nationwide initiative to promote the use of generic medicines and raise awareness about the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP). The seminar at GNIPST aligned with these national efforts, providing a platform for discussions on making quality medicines accessible and affordable to all. The event underscored the institute's commitment to supporting government initiatives aimed at improving public health through the promotion of generic medicines.



4.Placement: Srijia Goswami (B.Pharm, Class of 2025) on her placement at Cytobiologics Pvt. Ltd.



5.Placement: Sahalee Paul and Sandra Tiwari from B. Pharm, Class of 2025, GNIPST, for securing placement at Cipla

6. Placement: Arindam Chatterjee and SK. Mijanur Rahaman, B. Pharm Class of 2025 at GNIPST, for securing placements at Fresenius Kabi



MORE INFORMATION >> www.gnipst.ac.in




GNIPST BULLETIN 2025

yes girl, you can.



INTERNATIONAL WOMEN'S DAY: CELEBRATING PROGRESS AND EMPOWERMENT

International Women's Day (IWD), observed annually on March 8th, is a global celebration of women's achievements in social, economic, cultural, and political spheres. It serves as a reminder of the ongoing fight for gender equality and women's rights. Originating from labor movements in the early 20th century, IWD has grown into a powerful platform for advocating women's empowerment, addressing gender-based challenges, and promoting inclusivity. Countries worldwide mark the occasion with events, campaigns, and initiatives aimed at fostering change and recognizing women's contributions to society. The day inspires collective action toward a more equitable world for future generations.




Significance of International Women's Day

- Raises awareness about gender inequality and women's rights.
- Celebrates the achievements of women in various fields.
- Encourages policies and actions that promote gender equality.
- Inspires individuals and organizations to support women's empowerment.
- Highlights challenges such as wage gaps, discrimination, and gender-based violence.
- Promotes leadership and opportunities for women in all sectors.
- Unites people globally in advocating for a fair and inclusive society.



GNIPST GAME TIME



Match the column A and B

A	B
1. 1st woman travel to space	1. Sucheta Kripalani
2. 1st woman to win an olympic gold medal	2. Marie Curie
3. 1st woman to win a Noble prize	3. Valentina Tereshkova
4. 1st woman chief minister of India	4. Armi Kuusela
5. 1st woman to win the Miss universe	5. Karnam Malleswari

Stay tuned for to the next edition for a shout out to fastest correct answers!

Submit your answer



SCAN
ME

or

CLICK
HERE

Cheers to the Victor!

Volume -2, Issue -1



Debanjan Bhattacharya

B.Pharm, 3rd Semester

Guru Nanak Institute of Pharmaceutical Science and Technology

Correct answers received from them also:

1. TULIKA DAS,
2. NEHA MONDAL,
3. RUPAM DALAL,
4. BANISHA MITRA



Editor-in-Chief

Prof. (Dr.) Abhijit Sengupta

Managing Editors

Prof. (Dr.) Lopamura Datta

Associate Editors

Mr. Tushar Adhikari

Ms. Manjarima Ganguli

Editorial Board Members

Mrs. Indrani Banerjee Chakraborty

Mr. Arpan Dutta

Ms. Ananya Chandra

Ms. Parnasree Chakraborty

Ms. Lopamudra Saha

Mr. Sarthak Saha



COURSES OFFERED

PHARMACY UG COURSES

- Bachelor of Pharmacy (B.Pharm)

PHARMACY DIPLOMA COURSES

- Diploma in Pharmacy (D.Pharm)

PHARMACY PG COURSES

- M.Pharm in Pharmaceutics
- M.Pharm in Pharmacology
- M.Pharm in Pharmaceutical Chemistry
- M.Pharm in Quality assurance
- M.Pharm in Regulatory Affairs
- M.Pharm in Pharmacognosy
- M.Pharm in Pharmaceutical Biotechnology

Major
Recruiters



**Latest
news**



www.gnipst.ac.in



www.facebook.com



www.instagram.com



www.linkedin.com



www.youtube.com



api.whatsapp.com



GNIPST BULLETIN 2025

yes
girl,
you
can.